{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:19:07Z","timestamp":1707524347572},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,15]]},"DOI":"10.7759\/cureus.17992","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T14:42:55Z","timestamp":1631716975000},"source":"Crossref","is-referenced-by-count":0,"title":["Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy"],"prefix":"10.7759","author":[{"given":"Shobha","family":"Mandal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barun","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srijana","family":"Baniya Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyson","family":"Poulose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineela","family":"Kasireddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona S","year":"2016","unstructured":"Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer?. BMC Med. 2016, 14:73. 10.1186\/s12916-016-0623-5","journal-title":"BMC Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo JA","year":"2018","unstructured":"Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018, 11:39. 10.1186\/s13045-018-0582-8","journal-title":"J Hematol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel JA","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018, 8:86. 10.3389\/fonc.2018.00086","journal-title":"Front Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer RJ","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, et al.. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015, 373:1803-13. 10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat S","year":"2017","unstructured":"Champiat S, Dercle L, Ammari S, et al.. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1. Clin Cancer Res. 2017, 23:1920-8. 10.1158\/1078-0432.CCR-16-1741","journal-title":"Clin Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4065\/83.3.355","article-title":"Small cell lung cancer","volume":"83","author":"Sher T","year":"2008","unstructured":"Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008, 83:355-67. 10.4065\/83.3.355","journal-title":"Mayo Clin Proc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21037\/qims.2018.08.02","article-title":"The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications","volume":"8","author":"Lim W","year":"2018","unstructured":"Lim W, Ridge CA, Nicholson AG, Mirsadraee S. The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. Quant Imaging Med Surg. 2018, 8:709-18. 10.21037\/qims.2018.08.02","journal-title":"Quant Imaging Med Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2015.08.002","article-title":"Lung cancer: biology and treatment options","volume":"1856","author":"Lemjabbar-Alaoui H","year":"2015","unstructured":"Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P. Lung cancer: biology and treatment options. Biochim Biophys Acta. 2015, 1856:189-210. 10.1016\/j.bbcan.2015.08.002","journal-title":"Biochim Biophys Acta"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.9.4272","article-title":"Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation","volume":"168","author":"Woo EY","year":"2002","unstructured":"Woo EY, Yeh H, Chu CS, et al.. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002, 168:4272-6. 10.4049\/jimmunol.168.9.4272","journal-title":"J Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.1342","article-title":"Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Masters GA","year":"2015","unstructured":"Masters GA, Temin S, Azzoli CG, et al.. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015, 33:3488-515. 10.1200\/JCO.2015.62.1342","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi FS","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, et al.. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363:711-23. 10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei H","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al.. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015, 373:1627-39. 10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.795944","article-title":"Cancer immunotherapies, their safety and toxicity","volume":"12","author":"Alatrash G","year":"2013","unstructured":"Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf. 2013, 12:631-45. 10.1517\/14740338.2013.795944","journal-title":"Expert Opin Drug Saf"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.05.003","article-title":"Cancer and the immune system: basic concepts and targets for intervention","volume":"42","author":"Pardoll D","year":"2015","unstructured":"Pardoll D. Cancer and the immune system: basic concepts and targets for intervention. Semin Oncol. 2015, 42:523-38. 10.1053\/j.seminoncol.2015.05.003","journal-title":"Semin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2019.100885","article-title":"Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: an autopsy case study","volume":"28","author":"Tanaka Y","year":"2019","unstructured":"Tanaka Y, Matsubara O, Asada K, Muramatsu A, Suzuki M, Shirai T. Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: an autopsy case study. Respir Med Case Rep. 2019, 28:100885. 10.1016\/j.rmcr.2019.100885","journal-title":"Respir Med Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz LH","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, et al.. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016, 62:132-7. 10.1016\/j.ejca.2016.03.081","journal-title":"Eur J Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"4","author":"Ferrara R","year":"2018","unstructured":"Ferrara R, Mezquita L, Texier M, et al.. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018, 4:1543-52. 10.1001\/jamaoncol.2018.3676","journal-title":"JAMA Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112674","article-title":"Hyperprogression under immunotherapy","volume":"20","author":"Frelaut M","year":"2019","unstructured":"Frelaut M, Le Tourneau C, Borcoman E. Hyperprogression under immunotherapy. Int J Mol Sci. 2019, 20:2674. 10.3390\/ijms20112674","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2020.11.7.6","article-title":"Pseudoprogression and immunotherapy phenomena","volume":"11","author":"Waxman ES","year":"2020","unstructured":"Waxman ES, Lee Gerber D. Pseudoprogression and immunotherapy phenomena. J Adv Pract Oncol. 2020, 11:723-31. 10.6004\/jadpro.2020.11.7.6","journal-title":"J Adv Pract Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.1381","article-title":"Pembrolizumab-induced hyperprogression in patient with non-small cell lung cancer","volume":"158","author":"Mandal S","year":"2020","unstructured":"Mandal S, Poulose J, Sulaiman L, Kasireddy V\r\n. Pembrolizumab-induced hyperprogression in patient with non-small cell lung cancer. Chest. 2020, 158:A1536. 10.1016\/j.chest.2020.08.1381","journal-title":"Chest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/66927-hyperprogression-a-unique-phenomenon-of-progression-of-existing-tumor-secondary-to-immunotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:40Z","timestamp":1707507220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/66927-hyperprogression-a-unique-phenomenon-of-progression-of-existing-tumor-secondary-to-immunotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.17992","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,15]]}}}